Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 3/20 | 0.38 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | ADH5 | P11766 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367942 | 0.84 | CREBBP (0.41) | PTGS2HPGDSCREBBPXDHGP6 | |
| SCHEMBL876522 | 0.83 | CYP2A6 (0.50) | CYP2A6PTGS2HPGDSPPARAXDH | |
| SCHEMBL876489 | 0.72 | ADH5 (0.51) | CYP2A6PTGS2PPARAXDHADH5 | |
| SCHEMBL877319 | 0.72 | HTT (0.50) | PTGS2HPGDSCREBBPXDHGP6 | |
| SCHEMBL2485944 | 0.69 | CYP2A6 (1.00) | CYP2A6HPGDSPPARAXDHGP6 | |
| SCHEMBL29394988 | 0.69 | CYP2A6 (1.00) | CYP2A6HPGDSPPARAXDHGP6 | |
| Ammonia Solution, Strong SCHEMBL1733225 | 0.68 | CYP2A6 (0.96) | CYP2A6HPGDSPPARAXDHGP6 | |
| SCHEMBL5017 | 0.65 | HPGDS (0.78) | CYP2A6PTGS2HPGDSXDHGP6 | |
| Hydrochloric Acid SCHEMBL30810801 | 0.63 | HPGDS (0.75) | CYP2A6PTGS2HPGDSXDHGP6 | |
| SCHEMBL4983079 | 0.63 | HPGDS (0.75) | CYP2A6PTGS2HPGDSXDHGP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9283213-B2 | Dihydropyridin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | claimed |
| EP-2592934-B1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | NIVALIS THERAPEUTICS INC (US) | 2015-08-26 | — | — | EP | claimed |
| US-20150157616-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | NIVALIS THERAPEUTICS, INC. | 2015-06-11 | — | — | US | claimed |
| US-8946434-B2 | Dihydropyridin-2(1H)-one compound as S-nirtosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists | N30 PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | claimed |
| EP-2592934-A1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | N30 Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| US-20130096161-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | N30 PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | claimed |
| WO-2012009227-A1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | N30 PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | WO | claimed |
| US-9283213-B2 | Dihydropyridin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9283213-B2 | Dihydropyridin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2592934-B1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | NIVALIS THERAPEUTICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2592934-B1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | NIVALIS THERAPEUTICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20150157616-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | NIVALIS THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150157616-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | NIVALIS THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8946434-B2 | Dihydropyridin-2(1H)-one compound as S-nirtosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists | N30 PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2592934-A1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | N30 Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20130096161-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | N30 PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096161-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | N30 PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096161-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | N30 PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2012009227-A1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | N30 PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009227-A1 | NOVEL DIHYDROPYRIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS AND NEUROKININ-3 RECEPTOR ANTAGONISTS | N30 PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096161-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | QDPR, TACR1, TACR2 | CYP2A6 1325/4885PTGS2 179/4885HPGDS 370/4885 |
| US-20150157616-A1 | Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists | QDPR, TACR1, TACR2 | CYP2A6 1325/4885PTGS2 179/4885HPGDS 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.